Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2017-09-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle
(Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib
hydrochloride work in treating patients with metastatic breast cancer. Drugs used in
chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as bevacizumab, can prevent cancer growth by
blocking the ability of cancer cells to grow and spread. Erlotinib hydrochloride may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial
evaluates a maintenance treatment with erlotinib and bevacizumab after Nab-paclitaxel and
bevacizumab which may control cancer growth with biologic therapies.